NYSE:EBS - Emergent Biosolutions Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $53.97 +1.16 (+2.20 %) (As of 04/24/2019 03:56 PM ET)Previous Close$52.81Today's Range$52.40 - $54.4652-Week Range$46.93 - $73.89Volume9,567 shsAverage Volume509,134 shsMarket Capitalization$2.77 billionP/E Ratio23.15Dividend YieldN/ABeta1.33 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; RSDL (Reactive Skin Decontamination Lotion Kit), a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard for intramuscular self-injection of atropine sulfate and obidoxime chloride. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for treating botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. Further, it provides NuThrax, an anthrax vaccine; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; ADENOVIRUS 4/7, a live attenuated vaccine; rVSV-Lassa, a vaccine for prevention of Lassa fever; rVSV-Marburg, a vaccine for prevention of Marburg hemorrhagic fever; rVSV-Sudan, vaccine for prevention of Sudan hemorrhagic fever; rVSV-QUAD, a vaccine for prevention of hemorrhagic fever; and rVSV-Ebola, a vaccine for prevention of Ebola hemorrhagic fever. Additionally, the company offers FLU-IGIV to treat Influenza A infection in hospitalized patients; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract manufacturing services to third-party customers. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland. Receive EBS News and Ratings via Email Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNYSE:EBS Previous Symbol CUSIP29089Q10 CIK1367644 Webwww.emergentbiosolutions.com Phone240-631-3200Debt Debt-to-Equity Ratio0.78 Current Ratio3.10 Quick Ratio2.07Price-To-Earnings Trailing P/E Ratio23.15 Forward P/E Ratio17.13 P/E Growth0.84 Sales & Book Value Annual Sales$782.40 million Price / Sales3.54 Cash Flow$3.6368 per share Price / Cash Flow14.84 Book Value$19.84 per share Price / Book2.72Profitability EPS (Most Recent Fiscal Year)$2.33 Net Income$62.70 million Net Margins8.02% Return on Equity12.61% Return on Assets8.53%Miscellaneous Employees1,705 Outstanding Shares51,382,000Market Cap$2.77 billion Next Earnings Date5/2/2019 (Confirmed) OptionableOptionable Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions What is Emergent Biosolutions' stock symbol? Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS." How will Emergent Biosolutions' stock buyback program work? Emergent Biosolutions declared that its Board of Directors has authorized a stock repurchase plan on Friday, March 23rd 2018, which allows the company to buyback $50,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company's board believes its shares are undervalued. How were Emergent Biosolutions' earnings last quarter? Emergent Biosolutions Inc (NYSE:EBS) released its quarterly earnings results on Thursday, February, 21st. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.61 by $0.14. The biopharmaceutical company earned $270.70 million during the quarter, compared to the consensus estimate of $269.05 million. Emergent Biosolutions had a net margin of 8.02% and a return on equity of 12.61%. The firm's revenue was up 39.7% compared to the same quarter last year. During the same period last year, the firm posted $0.74 earnings per share. View Emergent Biosolutions' Earnings History. When is Emergent Biosolutions' next earnings date? Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Emergent Biosolutions. How can I listen to Emergent Biosolutions' earnings call? Emergent Biosolutions will be holding an earnings conference call on Thursday, May 2nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8557666521. What guidance has Emergent Biosolutions issued on next quarter's earnings? Emergent Biosolutions issued an update on its first quarter 2019 earnings guidance on Thursday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $185-205 million, compared to the consensus revenue estimate of $213.07 million.Emergent Biosolutions also updated its FY 2019 guidance to EPS. What price target have analysts set for EBS? 6 brokerages have issued 1-year target prices for Emergent Biosolutions' stock. Their predictions range from $64.00 to $80.00. On average, they expect Emergent Biosolutions' stock price to reach $72.1667 in the next year. This suggests a possible upside of 33.7% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions. What is the consensus analysts' recommendation for Emergent Biosolutions? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions. What are Wall Street analysts saying about Emergent Biosolutions stock? Here are some recent quotes from research analysts about Emergent Biosolutions stock: 1. Cantor Fitzgerald analysts commented, "As investors appreciate the durability and revenue potential of Emergent’s portfolio, we expect upward earnings revisions and multiple expansion to drive the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $75. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of DCF and EV/EBITDA to get to our PT of $75." (4/21/2019) 2. According to Zacks Investment Research, "Emergent BioSolutions' recent acquisitions of PaxVax and Adapt Pharma have expanded the company’s presence in the public health threats market. Its anthrax vaccine, NuThrax’s regulatory application is under review, with a decision expected in the first half of 2019. We are positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the cost structure. Notably, the company derives majority of its revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is a headwind. Moreover, Emergent depends on certain single-source suppliers for key materials and services, which are necessary for manufacturing BioThrax. This, in turn, raises a concern. Shares of the company have underperformed the industry so far this year. Estimates have narrowed ahead of Q1 earnings. Emergent has a mixed record of earnings surprises in the recent quarters." (4/8/2019) Has Emergent Biosolutions been receiving favorable news coverage? Media stories about EBS stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Emergent Biosolutions earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. Who are some of Emergent Biosolutions' key competitors? Some companies that are related to Emergent Biosolutions include Genmab A/S (GNMSF), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Marina Biotech (MRNA), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), GALAPAGOS NV/S (GLPG) and Amarin (AMRN). What other stocks do shareholders of Emergent Biosolutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include Mercadolibre (MELI), Broadcom (AVGO), Global Payments (GPN), Micron Technology (MU), Netflix (NFLX), NXP Semiconductors (NXPI), AbbVie (ABBV), NVIDIA (NVDA), Gentherm (THRM) and CalAmp (CAMP). Who are Emergent Biosolutions' key executives? Emergent Biosolutions' management team includes the folowing people: Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 61)Mr. Robert G. Kramer Sr., CEO, Pres & Director (Age 62)Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 46)Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 48)Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 55) Who are Emergent Biosolutions' major shareholders? Emergent Biosolutions' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.58%), Tributary Capital Management LLC (0.25%), Pier Capital LLC (0.21%), Strs Ohio (0.16%), Foundry Partners LLC (0.10%) and Eqis Capital Management Inc. (0.08%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions. Which major investors are selling Emergent Biosolutions stock? EBS stock was sold by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Eqis Capital Management Inc., Foundry Partners LLC, Meeder Asset Management Inc., Nisa Investment Advisors LLC and CAPROCK Group Inc.. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Ronald Richard and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions. Which major investors are buying Emergent Biosolutions stock? EBS stock was bought by a variety of institutional investors in the last quarter, including Pier Capital LLC, Peregrine Capital Management LLC, Tributary Capital Management LLC, Virtu Financial LLC, Financial Gravity Wealth Inc., Strs Ohio, First Hawaiian Bank and Huntington National Bank. View Insider Buying and Selling for Emergent Biosolutions. How do I buy shares of Emergent Biosolutions? Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Emergent Biosolutions' stock price today? One share of EBS stock can currently be purchased for approximately $53.97. How big of a company is Emergent Biosolutions? Emergent Biosolutions has a market capitalization of $2.77 billion and generates $782.40 million in revenue each year. The biopharmaceutical company earns $62.70 million in net income (profit) each year or $2.33 on an earnings per share basis. Emergent Biosolutions employs 1,705 workers across the globe. What is Emergent Biosolutions' official website? The official website for Emergent Biosolutions is http://www.emergentbiosolutions.com. How can I contact Emergent Biosolutions? Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected] MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 320 (Vote Outperform)Underperform Votes: 274 (Vote Underperform)Total Votes: 594MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/24/2019 by MarketBeat.com StaffFeatured Article: How is Preferred Stock Different from Common Stock?